Zhi Hong, Brii Bio CEO (file photo)
July 13, 2021 10:32 AM EDTUpdated 10:49 AM
Financing
China

Bap­tized by Covid-19 fire, Brii Bio reaps $320M Hong Kong IPO to car­ry on with pipeline for in­fec­tious dis­eases and be­yond

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

FDA pos­es ef­fi­ca­cy, safe­ty ques­tions over four can­cer drugs ahead of two-day ad­comm

Up­dat­ed: No­vo Nordisk CEO to step down amid stock de­cline, time­line for suc­ces­sor un­known

HHS can re­quire ap­proval for drug­mak­ers to ap­ply 340B re­bate mod­els, court rules

No­vo Nordisk’s glob­al obe­si­ty leader is mov­ing on; Flag­ship biotech gets CEO from Schol­ar Rock

A service from the Financial Times